Hilton Santa Fe Historic Plaza Hotel Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2016



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Hemorrhagic Fever Viruses (S3)


Organizer(s) William E. Dowling and Thomas W. Geisbert
December 4—8, 2016
Hilton Santa Fe Historic Plaza Hotel • Santa Fe, New Mexico USA
Discounted Abstract Deadline: Aug 4, 2016
Abstract Deadline: Sep 12, 2016
Scholarship Deadline: Aug 4, 2016
Discounted Registration Deadline: Oct 4, 2016

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Summary of Meeting:
Viral Hemorrhagic Fevers (VHF) are caused by a disparate group of viruses from four different virus families – Arenaviruses, Bunyaviruses, Filoviruses and Flaviviruses. These viruses have a substantial public health impact with few effective vaccines or antivirals available. Although their structures, vectors and replication cycles are very different, there are common pathogenic features between them. The meeting is designed to bring together the research communities around these individual viral families, to explore common pathways and mechanisms employed by the viruses, to discuss current medical countermeasures, and to foster collaborations. The specific aims of the conference are to: 1) Discuss the methods employed by hemorrhagic fever viruses to subvert host innate immune responses; 2) Assess the mechanisms causing endothelial dysfunction and coagulopathy that are hallmarks of VHF disease; 3) Look at the contributions of host genetics in disease progression; 4) Describe the state of the art in diagnostics; and 5) Present data on promising candidate vaccines and therapeutics. This symposium will occupy a unique niche as there is not a current scientific conference which brings these communities together in a focused manner.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Sunday, December 4 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, December 8 with a closing plenary session from 17:00 to 20:00, followed by a social hour and entertainment. We recommend return travel on Friday, December 9 in order to fully experience the meeting.

SUNDAY, DECEMBER 4

4:00—8:00 PM
Arrival and Registration

Promenade
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Promenade

MONDAY, DECEMBER 5

7:30—8:30 AM
Breakfast

Pecos/Canyon
8:30—9:30 AM
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* William E. Dowling, NIAID, National Institutes of Health, USA

* Thomas W. Geisbert, University of Texas Medical Branch, USA

Erica Ollmann Saphire, The Scripps Research Institute, USA
The Molecular Tool-Kit of Hemorrhagic Fever Viruses

9:30 AM—12:15 PM
Innate Immune Evasion I
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Erica Ollmann Saphire, The Scripps Research Institute, USA

Christopher F. Basler, Georgia State University, USA
Ebola Virus VP35 and VP24 are Innate Immune Suppressors and Virulence Determinants

Coffee Break

Elke Mühlberger, Boston University, USA
Silence Is Golden – Distinct Host Responses in Human Macrophages Infected with High or Low Pathogenic Ebolaviruses

Juan Carlos de la Torre, The Scripps Research Institute, USA
Novel Strategies to Developing Therapeutics and Vaccines to Combat Hemorrhagic Fever Arenaviruses

Ana Fernandez-Sesma, Mount Sinai School of Medicine, USA
Modulation of Innate Immunity by Dengue Virus

12:15—2:30 PM
On Own for Lunch

12:15—1:00 PM
Poster Setup

Mesa C
1:00—10:00 PM
Poster Viewing

Mesa C
2:30—4:30 PM
Workshop 1: Innate Immune Evasion II

Mesa A-B
* Christopher F. Basler, Georgia State University, USA

Gaya Amarasinghe, Washington University School of Medicine, USA
Role of Ebola Viral VP24 Protein in Immune Evasion

Hinh Ly, University of Minnesota, Twin Cities, USA
Molecular Mechanisms of Inhibition of Antigen-Presenting Cells by Human Hemorrhagic Fever-Causing Arenaviruses

Colm Atkins, University of Texas Medical Branch, USA
Rift Valley Fever Virus Infection in Human Neuronal Cells

Daniel Stephen Chertow, National Institutes of Health, USA
Role of Ebola Virus Proteins in Bystander Lymphocyte Apoptosis

Lilia Melnik, Tulane University, USA
The Ebola Virus Delta-Peptide Has Viroporin-Like Activity

Jessica R. Spengler, Centers for Disease Control and Prevention, USA
Crimean-Congo Hemorrhagic Fever Virus Strain-Dependent Disease in Humanized Mice

Emily Speranza, Boston University, USA
Delineating Survival from Fatal Outcome in Ebola Virus Disease in Humans

4:30—5:00 PM
Coffee Available

Promenade
5:00—7:00 PM
Host Genetics
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Cesar Muñoz Fontela, Heinrich Pette Institute, Germany
Dissecting Human Immunity to Ebola Virus

Jan E. Carette, Stanford University, USA
Host Factors Involved in Pathogenesis of HFV

Beatriz de la Caridad Sierra Vázquez, Pedro Kouri Institute for Tropical Medicine, PAHO/WHO Collaborating Center, Cuba
Short Talk: Lipid/Cholesterol Metabolism Involved in Viral Replication and Immune Response Provide African-Ancestry Protection Against Dengue Hemorrhagic

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Pecos/Canyon
7:30—10:00 PM
Poster Session 1

Mesa C

TUESDAY, DECEMBER 6

7:30—8:30 AM
Breakfast

Pecos/Canyon
8:30—11:45 AM
Endothelial Dysfunction and Coagulopathy I
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Nigel Mackman, University of North Carolina at Chapel Hill, USA
Coagulation Cascade Activation during Viral Infection

Lisa E. Hensley, NIAID, National Institutes of Health, USA
Late-Stage Filovirus Disease in NHPs

Coffee Break

Anita K. McElroy, Emory University, USA
Endothelial Dysfunction and Coagulopathy during Ebola Virus Disease in Humans

Stefan Kunz, Lausanne University Hospital, Switzerland
Molecular Mechanisms underlying Lassa Virus Invasion of Vascular Endothelial Cells

Dennis A. Bente, University of Texas Medical Branch, USA
Crimean-Congo Hemorrhagic Fever Virus in of the Transmission and Pathogenesis: Current Considerations

11:45 AM—2:30 PM
On Own for Lunch

11:45 AM—1:00 PM
Poster Setup

Mesa C
1:00—10:00 PM
Poster Viewing

Mesa C
2:30—3:30 PM
Workshop 2A: Endothelial Dysfunction and Coagulopathy II

Mesa A-B
* Lisa E. Hensley, NIAID, National Institutes of Health, USA

Roberto Aiolfi, The Scripps Research Institute, USA
Defective Platelet Thromboxane A2 Signaling and Serotonin Release in the Pathogenesis of Bleeding during Viral Infection

Anne-Marie Connolly-Andersen, Umeå University, Sweden
Pulmonary Endothelial Glycocalyx Degradation in Hantavirus Infection

Ashley St. John, Duke-National University of Singapore, Singapore
Dengue Virus-Elicited Tryptase Breaks Tight Junctions to Induce Endothelial Permeability and Shock

Brian Martin Sullivan, The Scripps Research Institute, USA
Linking Platelet Dysfunction to Cytotoxic T Cell Responses during Lethal Viral Hemorrhagic Fever Infection

3:30—4:30 PM
Workshop 2B: Clinical and Immunologic Findings during Lassa Infection

Mesa A-B
* Colleen S. Kraft, Emory University, USA

Aneesh K. Mehta, Emory University, USA
Novel Insights into the Clinical Care of Lassa Disease

Anita K. McElroy, Emory University, USA
The Human Innate and Adaptive Immune Response to Lassa Virus Infection: A Case Study

Lisa Oestereich, Heinrich Pette Institute, Germany
Human Immune Responses to Lassa Infection in Nigeria

4:30—5:00 PM
Coffee Available

Promenade
5:00—7:00 PM
Diagnostics
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Jonathan S. Towner, Centers for Disease Control and Prevention, USA
Filovirus Replication in Naturally and Experimentally Infected Bats

Stephan Günther, Bernhard-Nocht-Institut für Tropenmedizin, Germany
Diagnosis of Ebola Virus Disease during the Outbreak in West Africa

John H. Connor, Boston University School of Medicine, USA
Short Talk: Real-Time Visualization of Individual Hemorrhagic Fever Virions in Solution

Frederick Holtsberg, Integrated Biotherapeutics, USA
Short Talk

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Pecos/Canyon
7:30—10:00 PM
Poster Session 2

Mesa C

WEDNESDAY, DECEMBER 7

7:30—8:30 AM
Breakfast

Pecos/Canyon
8:30—11:30 AM
Vaccines I
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA

Michael Egan, Profectus Biosciences, USA
Filovirus rVSV Vaccines

Sheri Dubey, Merck & Co., Inc., USA
Clinical Development of a Recombinant Ebola Vaccine in the Midst of an Unprecedented Outbreak

Coffee Break

Heinz Feldmann, Rocky Mountain Laboratories, USA
Lassa rVSV Vaccines

Andrea Marzi, NIAID, National Institutes of Health, USA
Short Talk: Efficacy of VSV-EBOV Post-Exposure Treatment in Rhesus Macaques Infected with EBOV-Makona

Farshad Guirakhoo, GeoVax, Inc., USA
Short Talk: MVA-VLP Platform for Development of a Single Dose Tetravalent Vaccine against Hemorrhagic Fever Viruses

Igor Lukashevich, University of Louisville, USA
Short Talk: Reassortant ML29 Vaccine Platform to Control Lassa Fever in West Africa

11:30 AM—5:00 PM
On Own for Lunch

11:30 AM—1:00 PM
Poster Setup

Mesa C
1:00—10:00 PM
Poster Viewing

Mesa C
4:30—5:00 PM
Coffee Available

Promenade
5:00—7:00 PM
Vaccines II
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Heinz Feldmann, Rocky Mountain Laboratories, USA

Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA
The Live Attenuated Dengue Vaccines TV003 and TV005 Completely Protect Against DENV-2 Infection in a Controlled Dengue Human Challenge Model

Shinji Makino, University of Texas Medical Branch, USA
Development of a Single-Cycle Replicable Rift Valley Fever Virus Vaccine

Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA
Clinical Assessment of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome (HFRS)

Courtney Brooke Woolsey, University of Texas Medical Branch, USA
Short Talk: A Recombinant Vesicular Stomatitis Virus-Based Vaccine Mediates Post-Exposure Protection against Marburg Virus Angola in Rhesus Macaques

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Pecos/Canyon
7:30—10:00 PM
Poster Session 3

Mesa C

THURSDAY, DECEMBER 8

7:30—8:30 AM
Breakfast

Pecos/Canyon
8:30—11:45 AM
Therapeutics I
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Andrea Marzi, NIAID, National Institutes of Health, USA

Larry Zeitlin, Mapp Biopharmaceutical, Inc., USA
Junin and Filovirus mAb Therapeutics

Thomas W. Geisbert, University of Texas Medical Branch, USA
Filovirus siRNA Therapeutics

Coffee Break

Luis M. Branco, Zalgen Labs, LLC, USA
Lassa Virus Human Monoclonal Antibody Therapeutics

Eric Bergeron, Centers for Disease Control and Prevention, USA
Short Talk: Antiviral Activity and Mechanism of Action of Site-1 Protease (S1P) Inhibitor on Crimean-Congo Hemorrhagic Fever Virus

Zachary Bornholdt, Mapp Biopharmaceutical, USA
The Structure-Based Design of a Pan-ebolavirus Immunotherapeutic Cocktail

Anna Z. Wec, Albert Einstein College of Medicine, USA
Short Talk: Bispecific Antibodies Targeting the Intracellular Virus-Receptor Interaction Provide Broad in vivo Protection Against Ebolaviruses

Bronwyn M. Gunn, Massachusetts General Hospital, USA
Short Talk: Antibody Fc-Effector Functionality Predicts Monoclonal Antibody-Mediated Post-Exposure Protection against Ebola Virus Challenge

11:45 AM—5:00 PM
On Own for Lunch

4:30—5:00 PM
Coffee Available

Promenade
5:00—7:15 PM
Therapeutics II
Meeting has ended...abstracts no longer viewable online.

Mesa A-B
* Chad E. Mire, Galveston National Laboratory, USA

Brian Gowen, Utah State University, USA
Prospects for Treatment of Severe Arenavirus and Bunyavirus Infections

M. Javad Aman, Integrated Biotherapeutics, Inc., USA
Short Talk: Cross-Protection Against Ebolaviruses with Vaccine Elicited Broadly Neutralizing Monoclonal Antibody Cocktails: Evidence for Cooperative Neutralization

Travis K. Warren, US Army Medical Research Institute of Infectious Diseases, USA
In vivo Efficacy of BCX4430 Against Ebola Virus

John Misasi, National Institutes of Health, USA
Protective Monotherapy Against Ebola Infection: Structure and Molecular Basis of Potent Neutralization

Ami Patel, Wistar Institute, USA
Short Talk: DNA-Delivery of Monoclonal Antibodies (DMAbs) as an Alternative, in vivo mAb Delivery Platform against Ebola Virus Infection

8:00—9:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Promenade/Mesa Ballroom
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Mesa Ballroom

FRIDAY, DECEMBER 9

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsor for generously supporting this meeting:

Bill & Melinda Gates Foundation

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI126804-01

Funding for this conference was made possible [in part] by 1 R13 AI 126804 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Mapp Biopharmaceutical, Inc.


Merck Vaccine Division


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676